AI Industry's Anthropomorphic Naming Trend Draws Criticism

Problem-focused framing that emphasizes potential harms of anthropomorphic language without substantial industry justification or nuance about naming conventions in technical fields.

This debate reflects tension between AI companies' marketing strategies and regulatory bodies' push for transparency. EU AI Act and similar regulations may gain leverage from this criticism, potentially shifting power toward stricter oversight frameworks and away from industry self-regulation. Anthropic's positioning as a 'safety-focused' company is challenged, affecting competitive dynamics with OpenAI and other AI leaders.

Similar to pharmaceutical industry's naming practices (e.g., 'Viagra' vs. 'sildenafil citrate'), where marketing language obscures technical reality. Regulatory response mirrors FDA's push for clearer medical terminology to prevent public misunderstanding.

Consumers may develop inflated expectations about AI capabilities based on human-like terminology, leading to disappointment, reduced adoption rates, or loss of trust when products underperform relative to marketing language. This could affect purchasing decisions and willingness to pay premium prices for AI-enhanced products.

Potential regulatory responses could include mandatory disclosure requirements about AI limitations, restrictions on anthropomorphic marketing language, or FTC scrutiny of deceptive naming practices. Regulators may require clearer technical documentation and consumer-facing disclaimers about what AI systems actually do versus implied human-like cognition.